test

A Phase Ib, Open-Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients with Non-Small Cell Lung Cancer with Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa)

Conditions

Non Small Cell Lung Cancer

What is the purpose of this trial?


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Boehringer Ingelheim Pharmaceuticals
Dates:
April 2011
Last Updated:
Study HIC#:
1010007517